Diabetes Clinical Trials in Wilmington

View 19 new treatments for Diabetes in Wilmington, NC near me. Every day, Power helps hundreds of Diabetes patients connect with leading medical research.
View 22 trials in Wilmington
Filter (22)

Mifepristone for Type 2 Diabetes

Corcept Clinic, Wilmington + 1 more

This trial is testing mifepristone, a medication that blocks cortisol, in patients with hard-to-control type 2 diabetes and high cortisol levels. The goal is to see if mifepristone can help manage their blood sugar better than standard treatments alone. Mifepristone has been studied for various conditions including Cushing's syndrome, psychotic depression, and cognitive decline in Alzheimer's disease.Show More
Recruiting
Phase 4
Est. 3 - 12 Weeks
Daniel Einhorn, MD
Study Director

Ranibizumab PDS Implant for Diabetic Retinopathy

Hoffmann-La Roche Clinic, Wilmington + 1 more

Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety of the Port Delivery System with Ranibizumab (PDS) Relative to the Comparator ArmShow More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
Clinical Trials
Study Director

BI 456906 for Diabetes and Obesity

Boehringer Ingelheim Clinic, Wilmington + 2 more

This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity who also have diabetes to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The study staff also regularly measure participants' body weight. The results are compared between the groups to see whether the treatment works.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Orforglipron for Type 2 Diabetes and Obesity

Eli Lilly Clinic, Wilmington + 1 more

This trial is testing a new diabetes medication called orforglipron to see if it is safer and more effective than insulin in people with type 2 diabetes who are overweight or obese and at higher risk for heart problems. The study will last several years and involve multiple visits.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Retatrutide for Type 2 Diabetes

Eli Lilly Clinic, Wilmington + 1 more

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Tirzepatide vs Dulaglutide for Type 2 Diabetes

Eli Lilly Clinic, Wilmington + 3 more

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Inclisiran for Cardiovascular Disease Prevention

Novartis Clinic, Wilmington + 1 more

This trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Novartis Pharmaceuticals
Study Director

CagriSema for Type 2 Diabetes

Novo Nordisk Clinic, Wilmington + 2 more

This trial tests CagriSema, a combination of semaglutide and cagrilintide, in people with type 2 diabetes. It aims to see if it can better manage blood sugar levels and reduce body weight by increasing insulin and reducing hunger. Semaglutide is known for lowering blood glucose levels and reducing appetite.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
Clinical Transparency (dept. 2834)
Study Director

PDS with Ranibizumab vs. Intravitreal Ranibizumab for Diabetic Macular Edema

Hoffmann-La Roche Clinic, Wilmington + 1 more

This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS with Ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal ranibizumab 0.5 mg every 4 weeks (Q4W). The substudy will evaluate the safety of re-implanting the updated PDS with ranibizumab and the refill-exchange procedures following re-implantation in participants with DME who were previously enrolled in the main Study, GR40550. Up to 100 participants from the main study will be enrolled and followed for a maximum of 72 weeks post-re-implantation in the substudy.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Clinical Trials
Study Director

Weekly vs Daily Insulin for Type 2 Diabetes

Novo Nordisk Clinic, Wilmington + 1 more

This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment participants get is decided by chance. Insulin icodec is the new medicine being tested, while insulin glargine is already approved and can be prescribed by doctors. Participants will get one injection of insulin icodec once a week, or one injection of insulin glargine once a day, depending on the treatment group participants are assigned into. Participants will use a pen with a small needle to inject the medicine under participants skin into participants thigh, upper arm or stomach.The study will last for about 9 months, but participants will only be taking the study medicine for 6 months.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 4 - 6 Weeks
Clinical Transparency (dept. 2834)
Study Director
Page 1 of 3

Frequently Asked Questions

How much do diabetes clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do diabetes clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across diabetes trials in Wilmington, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for diabetes patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Wilmington is research being conducted for diabetes?

Prominent hospitals in Wilmington conducting diabetes clinical trials include Alfred I duPont Hospital for Children. Several trials are also taking place in the central area, with approximately 9 ongoing as of 2024.

What promising new drugs are being tested?

In Wilmington, diabetes research includes treatments like Insulin and GLP-1 Receptor Agonists. Notable specific interventions being studied are Basal Insulin, Dulaglutide, and the Eversense® CGM system.